RN-1101 (Rui Therapeutics)

N/A

Report date: 2025/07/25 14:30:08

Base Information

Drug NameRN-1101 (Rui Therapeutics)
Drug Alias NameRN-1101
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsB-cell maturation protein modulators
TargetsB-lymphocyte antigen CD19B-cell maturation protein
Therapy Area/IndicationsMultiple MyelomaLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShenzhen Rui Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Rui Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple MyelomaLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A